Cardiology Stem Cells Market Size is Predicted to Expand at a CAGR of 7.4% to Reach US$ 5.1 Billion by 2031 | Report Transparency Market Research

The global 𝐂𝐚𝐫𝐝𝐢𝐨𝐥𝐨𝐠𝐲 𝐒𝐭𝐞𝐦 𝐂𝐞𝐥𝐥𝐬 industry, valued at US$ 2.6 billion in 2022, is forecasted to achieve substantial growth, with a projected compound annual growth rate (CAGR) of 7.4% from 2023 to 2031. By the end of 2031, it is anticipated to surpass US$ 5.1 billion, indicating significant expansion within the period.

𝐆𝐞𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅:
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=85464&utm_source=OpenPR&utm_medium=OpenPR&utm_campaign=MansiR

The global cardiology stem cells market is experiencing growth, driven by the introduction of new and innovative therapies for heart disease treatment. Advancements in stem cell research, coupled with a rise in cardiovascular disease prevalence, are expected to fuel market expansion in the coming years. Moreover, increased healthcare spending and growing awareness of the benefits of early detection and treatment are anticipated to further drive market growth. 

𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐏𝐫𝐨𝐟𝐢𝐥𝐞𝐝-

Astellas Pharma, Inc.,STEMCELL Technologies,Cellular Engineering Technologies,BioTimes, Inc.,Takara Bio, Inc.,U.S. Stem Cell, Inc.,BrainStorm Cell Limited.,Cytori Therapeutics, Inc.,Lisata Therapeutics,Bio Cardia, Inc.

𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧:

𝐓𝐲𝐩𝐞 𝐨𝐟 𝐂𝐞𝐥𝐥

Embryonic Stem Cells
Adult Stem Cells
Induced Pluripotent Stem Cells
Cord Blood Stem Cells and Amniotic Fluid Stem Cells

𝐀𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧

Heart Failure
Myocardial Infarction
Critical Limb Ischemia
Others

𝐒𝐨𝐮𝐫𝐜𝐞

Autologous
Allogenic

𝐄𝐧𝐝-𝐮𝐬𝐞𝐫

Pharmaceutical & Biotechnology Companies
Hospitals & Cell Banks
Academic & Research Institutes

𝐆𝐞𝐭 𝐓𝐡𝐢𝐬 𝐄𝐱𝐜𝐥𝐮𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭, 𝐈𝐧𝐬𝐭𝐚𝐧𝐭𝐥𝐲:
https://www.transparencymarketresearch.com/checkout.php?rep_id=85464<ype=S&utm_source=OpenPR&utm_medium=OpenPR&utm_campaign=MansiR

𝐊𝐞𝐲 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭𝐬:

In December 2022, Bio Cardia, Inc., an inventor of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced the Food and Drug Administration (FDA) approval for its Investigational New Drug (IND) application to initiate a first-in-human phase I/II clinical trial of its Neurokinin-1 receptor positive (NK1R+) allogeneic human mesenchymal stem cell (MSC) therapy for the treatment of patients with ischemic heart failure

In May 2021, Kalyagen, along with the Sociedad Espanola de Medicina Regenerativa y Terapia Celular (the "Spanish Society of Regenerative Medicine and Cell Therapy"), announced the launch of a multicenter clinical trial, "The Effect of Stemregen and Adipose Stroma Vascular Fraction (SVF) Either Individually or in Combination in Patient with Heart Failure," to evaluate the use of stem cell therapies in patients suffering from heart failure. STEMREGEN is a natural stem cell enhancer documented to increase the number of circulating stem cells by stimulating endogenous stem cell mobilization (ESCM).

𝐑𝐞𝐠𝐢𝐨𝐧𝐚𝐥 𝐎𝐮𝐭𝐥𝐨𝐨𝐤:

In 2021, North America dominated the global market, and it is poised for substantial growth with a high CAGR expected from 2022 to 2031. This region boasts numerous leading stem cell research centers, institutes, and companies dedicated to advancing stem cell-based therapies. Meanwhile, Asia Pacific took the lead in the cardiology stem cells market in 2022, anticipating rapid growth between 2023 and 2031.

Notably, countries like Japan, South Korea, China, and Singapore are driving innovation in stem cell research and development, supported by robust investment and regulatory frameworks. Japan, in particular, stands out with its well-established regulatory framework and ongoing clinical trials to evaluate the safety and efficacy of stem cell therapies across various diseases.

𝐁𝐫𝐨𝐰𝐬𝐞 𝐌𝐨𝐫𝐞 𝐑𝐞𝐩𝐨𝐫𝐭𝐬 𝐛𝐲 𝐓𝐌𝐑:

𝐁𝐢𝐨𝐫𝐞𝐬𝐨𝐫𝐛𝐚𝐛𝐥𝐞 𝐕𝐚𝐬𝐜𝐮𝐥𝐚𝐫 𝐒𝐜𝐚𝐟𝐟𝐨𝐥𝐝 𝐌𝐚𝐫𝐤𝐞𝐭- https://www.globenewswire.com/news-release/2023/06/07/2684214/0/en/Bioresorbable-Vascular-Scaffold-Market-Set-to-Grow-at-a-Remarkable-7-8-CAGR-Says-TMR-Study.html

𝐒𝐞𝐦𝐢𝐜𝐨𝐧𝐝𝐮𝐜𝐭𝐨𝐫 𝐈𝐂𝐏-𝐌𝐒 𝐒𝐲𝐬𝐭𝐞𝐦 𝐌𝐚𝐫𝐤𝐞𝐭- https://www.globenewswire.com/news-release/2023/06/07/2684188/0/en/Semiconductor-ICP-MS-System-Market-to-Grow-at-a-CAGR-of-4-7-during-the-2023-to-2031-Forecast-Period-TMR-Study.html

𝐀𝐛𝐨𝐮𝐭 𝐓𝐫𝐚𝐧𝐬𝐩𝐚𝐫𝐞𝐧𝐜𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

𝐂𝐨𝐧𝐭𝐚𝐜𝐭:

Nikhil Sawlani
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com        
Email: sales@transparencymarketresearch.com

This release was published on openPR.